🇺🇸 Sulphonylureas in United States

6 US adverse-event reports

Marketing authorisation

FDA

• Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 6

Most-reported reactions

1. Asthenia — 1 report (16.67%)
2. Drug Ineffective — 1 report (16.67%)
3. Drug Interaction — 1 report (16.67%)
4. Hyperglycaemia — 1 report (16.67%)
5. Nausea — 1 report (16.67%)
6. Vomiting — 1 report (16.67%)

Source database →

Frequently asked questions

Is Sulphonylureas approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Sulphonylureas in United States?

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders is the originator. The local marketing authorisation holder may differ — check the official source linked above.